NCAM1 and neuroblastoma: Figure 3 shows binding of the subclass-matched irrelevant mAb IgG2b compared to SEAM 3, the anti-GD3 mAb R24 and anti-NCAM (CD56) mAb binding to SK-MEL-28 melanoma and SH-SY5Y neuroblastoma cells in the absence and presence of Triton X-100 treatment, as indicated.